If “Science has a really serious marketing problem” as Larry Page observed, then life extension technologies face even bigger marketing problems. I am definitely not a marketing expert but realized the problem early on when thinking about the lag-phase period of a robust life extension technology. So I made a short email interview with Dave… Continue reading The marketing problem of life extension technologies
Recently I wrote a meeting report on the SENS3 conference for a very prestigious science journal, but finally it did not go through the filters. I knew that the chance for publication is small as the journal rarely publish such meeting reports and as it was in many respects an unconventional science conference. The standards… Continue reading Unpublished SENS3 conference report for mainstream scientists!
The Nobel Assembly at Karolinska Institute has today decided to award The Nobel Prize in Physiology or Medicine for 2007 jointly to Mario R. Capecchi, Martin J. Evans and Oliver Smithies for their discoveries of “principles for introducing specific gene modifications in mice by the use of embryonic stem cells” Link It’s rather a 2/3… Continue reading The first stem cell related Nobel prize: Martin Evans, 2007
Linda Powers is the managing director and co-founder of Toucan Capital Corp, a $120 million venture capital fund (SBIC) focused on seed and early-stage life science and advanced technology investments (the fund markets itself as the The Leading US Investor in Stem Cells and Regenerative Medicine). Out of here insights and facts presented on the… Continue reading SENS3: The stem cell marketplace by Linda Powers, Tucan Capital (slides)
Source and list are on the SENS3 website.
Rutledge Ellis-Behnke from M.I.T. talked on “a nano hemostatic agent that immediately stops bleeding. Hemostasis is a major problem after trauma and during surgery; as much as 50% of surgical time can be spent packing wounds to reduce or control bleeding and there are few effective methods to stop it without causing secondary damage. We… Continue reading SENS3: Rutledge Ellis-Behnke on a quick nano hemostatic agent
Embedded on the slideshow below 9 slides of Michael Rose‘s presentation called Slowing and then stopping aging on the SENS3 conference on the 9th of September. (Photos made by me with the iPhone.) Rose’s argument was: Aubrey de Grey’s original SENS proposal is based on the non-evolutionary assumption that aging is a process of accumulating… Continue reading Michael Rose, evolutionary SENS and aging as a loss of adaptation (slides)